Logo image of TIL

INSTIL BIO INC (TIL) Stock Fundamental Analysis

NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD

22.12  -1.89 (-7.87%)

After market: 22.12 0 (0%)

Fundamental Rating

2

Taking everything into account, TIL scores 2 out of 10 in our fundamental rating. TIL was compared to 572 industry peers in the Biotechnology industry. While TIL seems to be doing ok healthwise, there are quite some concerns on its profitability. TIL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TIL had negative earnings in the past year.
TIL had a negative operating cash flow in the past year.
In the past 5 years TIL always reported negative net income.
In the past 5 years TIL always reported negative operating cash flow.
TIL Yearly Net Income VS EBIT VS OCF VS FCFTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

TIL has a Return On Assets of -27.58%. This is in the better half of the industry: TIL outperforms 71.58% of its industry peers.
TIL has a Return On Equity of -42.63%. This is in the better half of the industry: TIL outperforms 70.16% of its industry peers.
Industry RankSector Rank
ROA -27.58%
ROE -42.63%
ROIC N/A
ROA(3y)-39.98%
ROA(5y)-40.08%
ROE(3y)-52.91%
ROE(5y)-50.43%
ROIC(3y)N/A
ROIC(5y)N/A
TIL Yearly ROA, ROE, ROICTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

TIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TIL Yearly Profit, Operating, Gross MarginsTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for TIL has been reduced compared to 1 year ago.
Compared to 1 year ago, TIL has a worse debt to assets ratio.
TIL Yearly Shares OutstandingTIL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TIL Yearly Total Debt VS Total AssetsTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

TIL has an Altman-Z score of -2.56. This is a bad value and indicates that TIL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TIL (-2.56) is comparable to the rest of the industry.
TIL has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TIL (0.47) is worse than 74.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -2.56
ROIC/WACCN/A
WACCN/A
TIL Yearly LT Debt VS Equity VS FCFTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

TIL has a Current Ratio of 12.90. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.
TIL has a better Current ratio (12.90) than 85.08% of its industry peers.
TIL has a Quick Ratio of 12.90. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.
TIL has a Quick ratio of 12.90. This is amongst the best in the industry. TIL outperforms 85.26% of its industry peers.
Industry RankSector Rank
Current Ratio 12.9
Quick Ratio 12.9
TIL Yearly Current Assets VS Current LiabilitesTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

TIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.87%, which is quite impressive.
EPS 1Y (TTM)56.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TIL will show a very strong growth in Earnings Per Share. The EPS will grow by 20.43% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.44%
EPS Next 2Y20.14%
EPS Next 3Y20.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TIL Yearly Revenue VS EstimatesTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2M 4M 6M 8M 10M
TIL Yearly EPS VS EstimatesTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TIL. In the last year negative earnings were reported.
Also next year TIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TIL Price Earnings VS Forward Price EarningsTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TIL Per share dataTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

TIL's earnings are expected to grow with 20.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.14%
EPS Next 3Y20.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSTIL BIO INC

NASDAQ:TIL (2/21/2025, 8:00:01 PM)

After market: 22.12 0 (0%)

22.12

-1.89 (-7.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-19 2025-03-19/amc
Inst Owners78.56%
Inst Owner Change-98.11%
Ins Owners10.98%
Ins Owner Change0%
Market Cap144.44M
Analysts82.5
Price Target116.28 (425.68%)
Short Float %13.13%
Short Ratio7.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.2%
Min EPS beat(2)-66.31%
Max EPS beat(2)23.92%
EPS beat(4)2
Avg EPS beat(4)-19.43%
Min EPS beat(4)-66.31%
Max EPS beat(4)30.75%
EPS beat(8)4
Avg EPS beat(8)-77%
EPS beat(12)5
Avg EPS beat(12)-54.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.62%
PT rev (3m)13.62%
EPS NQ rev (1m)-6.86%
EPS NQ rev (3m)-6.86%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)-26.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-11.56
EYN/A
EPS(NY)-13.35
Fwd EYN/A
FCF(TTM)-10.5
FCFYN/A
OCF(TTM)-8.96
OCFYN/A
SpS0
BVpS27
TBVpS27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.58%
ROE -42.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.98%
ROA(5y)-40.08%
ROE(3y)-52.91%
ROE(5y)-50.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 257.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.9
Quick Ratio 12.9
Altman-Z -2.56
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1316.52%
Cap/Depr(5y)4909.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.96%
EPS Next Y46.44%
EPS Next 2Y20.14%
EPS Next 3Y20.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.54%
OCF growth 3YN/A
OCF growth 5YN/A